Risk for CKD, CVD Lower for Adults With Evidence of Type 2 Diabetes Remission
By Elana Gotkine HealthDay Reporter
FRIDAY, Jan. 26, 2024 -- Individuals with evidence of remission of type 2 diabetes have a considerably reduced risk for chronic kidney disease (CKD) and cardiovascular disease (CVD), according to a study published online Jan. 18 in Diabetologia.
Edward W. Gregg, Ph.D., from the Royal College of Surgeons of Ireland in Dublin, and colleagues conducted a multicenter randomized controlled trial comparing the effect of a 12-year intensive lifestyle intervention with that of diabetes support and education on CVD and other long-term outcomes. Based on achievement and duration of diabetes remission, the incidence of CVD and CKD was compared among 4,402 and 4,132 participants, respectively. CVD incidence was defined as any occurrence of nonfatal acute myocardial infarction, stroke, admission for angina, or CVD death; high-risk or very high-risk CKD were defined based on the Kidney Disease Improving Global Outcomes criteria.
The researchers found that in multivariate analyses adjusting for hemoglobin A1c, blood pressure, lipid levels, CVD history, diabetes duration, and intervention arm, the risks for CKD and the composite CVD measure were significantly reduced for participants with evidence of any remission during follow-up (hazard ratios, 0.67 and 0.60, respectively). Participants with evidence of longer-term remission had the greatest magnitude of risk reduction.
"As the first intervention study to associate remission with reduction of diabetes-related complications, this is encouraging news for those who can achieve remission from type 2 diabetes," Gregg said in a statement. "While our study is also a reminder that maintenance of weight loss and remission is difficult, our findings suggest any success with remission is associated with later health benefits."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted January 2024
Read this next
ENDO: Cardiovascular Events Occur Less Often With GLP1-RA, SGLT-2i for T2D, Liver Disease
FRIDAY, June 7, 2024 -- For adults with type 2 diabetes (T2D) and metabolic dysfunction-associated steatotic liver disease (MASLD), glucagon-like peptide 1 receptor agonists...
Diabetes Tied to Higher Prevalence of Overactive Bladder
TUESDAY, June 4, 2024 -- Markers of diabetes are positively associated with overactive bladder (OAB), according to a study published online April 28 in Frontiers in...
Semaglutide Cuts Risk for Kidney Outcomes, Death in CKD With T2DM
FRIDAY, May 31, 2024 -- For patients with type 2 diabetes and chronic kidney disease, semaglutide reduces the risk for clinically important kidney outcomes and death from...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.